Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by str8tgoodson Oct 29, 2010 12:59pm

582 Views

Post# 17631217

RE: News next week

Lots of excited traders it seems. So far looks good.

From the Oct. 6 news release results were to be expected within 4 - 6 weeks, but that was for all zones, and I believe that is when result will be released after all zones are tested.

So far it's been almost 3 weeks, so 1 more week at the least and we should get the flowrates.

So the Week of Nov. 8th would be the earliest to expect results. Should be fun leading up to that. GLTA

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!